Jpmorgan Chase & CO Argenx Se Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Argenx Se stock. As of the latest transaction made, Jpmorgan Chase & CO holds 6,294 shares of ARGX stock, worth $3.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,294

Previous 11,942 47.3%

Holding current value

$3.71 Million

Previous $4.7 Million 42.44%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$356.01 - $451.55 $2.01 Million - $2.55 Million	-5,648 Reduced 47.3%	6,294 $2.71 Million
Q1 2024 May 10, 2024	SELL	$356.95 - $413.29 $201,319 - $233,095	-564 Reduced 4.51%	11,942 $4.7 Million
Q4 2023 Feb 12, 2024	SELL	$338.91 - $506.01 $3.77 Million - $5.62 Million	-11,111 Reduced 47.05%	12,506 $4.76 Million
Q3 2023 Nov 14, 2023	SELL	$369.35 - $548.43 $21.8 Million - $32.3 Million	-58,913 Reduced 71.38%	23,617 $11.6 Million
Q2 2023 Aug 11, 2023	SELL	$360.14 - $422.58 $4.95 Million - $5.81 Million	-13,753 Reduced 14.28%	82,530 $32.2 Million
Q1 2023 May 11, 2023	BUY	$334.23 - $403.65 $15.3 Million - $18.5 Million	45,712 Added 90.39%	96,283 $35.9 Million
Q4 2022 Feb 13, 2023	BUY	$342.17 - $402.31 $3.51 Million - $4.13 Million	10,259 Added 25.45%	50,571 $19.2 Million
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $3.45 Million - $3.98 Million	10,056 Added 33.24%	40,312 $14.2 Million
Q2 2022 Aug 11, 2022	BUY	$269.58 - $378.88 $7.73 Million - $10.9 Million	28,679 Added 1818.58%	30,256 $11.5 Million
Q1 2022 May 11, 2022	BUY	$254.45 - $351.06 $236,129 - $325,783	928 Added 142.99%	1,577 $497,000
Q4 2021 Feb 10, 2022	SELL	$272.01 - $353.03 $59,026 - $76,607	-217 Reduced 25.06%	649 $227,000
Q3 2021 Nov 12, 2021	BUY	$295.0 - $350.58 $255,470 - $303,602	866 New	866 $262,000

Others Institutions Holding ARGX

# of Institutions

382

Shares Held

31.6M

Call Options Held

303K

Put Options Held

429K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $32.6B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Argenx Se Transaction History